Medical Information

Iqirvo, as a PPAR agonist drug, commonly has side effects including liver dysfunction, gastrointestinal reactions, and increased risk of infection, which need to be alleviated through regular monitoring and targeted measures. The following provides a detailed explanation from three aspects: classification of common side effects, serious reactions requiring urgent medical attention, and specific relief methods.

1. Common side effects and mitigation measures

(1) Abnormal liver function: Approximately 15% of patients experience elevated ALT/AST levels. It is recommended to test the baseline value before medication and have a follow-up every 4 weeks during treatment. If ALT>3 times the upper limit, medication should be reduced or suspended, and liver protection treatment should be combined.

(2) Gastrointestinal reactions: The incidence of nausea and diarrhea is about 20%. It is recommended to take it with meals in divided doses, and to supplement electrolyte solution when experiencing diarrhea. For severe cases, symptomatic treatment with loperamide may be considered.

(3) Risk of infection: May reduce white blood cell count. Avoid contact with infectious sources and seek medical attention promptly if fever or respiratory symptoms occur.

2. Serious reactions requiring immediate medical attention

(1) Drug induced liver injury: In the event of jaundice, upper right abdominal pain, or increased eosinophils, immediate discontinuation of medication is required, and the possibility of DI-ALH should be evaluated.

(2) Severe allergic reactions: facial/laryngeal edema, urticaria with difficulty breathing require emergency treatment, and adrenaline may be used if necessary.

(3) Symptoms of heart failure: including sudden weight gain, lower limb edema, or paroxysmal nocturnal dyspnea, requiring cardiac function assessment.

3. Long term medication management recommendations

(1) Monitoring plan: check the liver and kidney functions, blood lipids and blood routine every 3 months, and strengthen blood glucose monitoring for diabetes patients.

(2) Lifestyle: Avoid grapefruit products to prevent interactions, limit alcohol intake to reduce liver burden.

(3) Special population: Patients with cirrhosis are prohibited from using it, and elderly people over 75 years old need to strengthen adverse reaction monitoring.